PCSA Insider Trading (Processa Pharmaceuticals)
Insider Ownership Percentage: 26.50%
Insider Buying (Last 12 Months): $154,206.00
Insider Selling (Last 12 Months): $52,520.20
Processa Pharmaceuticals Share Price & Price History
Current Price: $1.58
Price Change: ▼ Price Decrease of -0.1 (-5.95%)
As of 05/17/2022 12:38 PM ET
The U.S. Solution to China's Copper Grab
From Investing Trends | Ad
China consumes 54% of the world's copper. Yet China mines only 8% of its copper needs, while plundering Africa, Latin America and South America for copper. The U.S. is left scrambling for new copper sources. But there's a North American copper sweet spot overlooked by China – for now.
Find Out Where This Copper Hotspot Is
Processa Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/6/2022 | Patrick Lin | Insider | Buy | 1,200 | $3.13 | $3,756.00 | 431,390 |  |
| 1/27/2022 | Justin W. Yorke | Director | Sell | 1,854 | $3.30 | $6,118.20 | | |
| 12/14/2021 | Patrick Lin | Insider | Buy | 3,000 | $4.00 | $12,000.00 | | |
| 12/6/2021 | Justin W. Yorke | Director | Sell | 4,200 | $4.71 | $19,782.00 | | |
| 12/3/2021 | Justin W. Yorke | Director | Sell | 5,500 | $4.84 | $26,620.00 | | |
| 12/3/2021 | Patrick Lin | Insider | Buy | 3,500 | $4.80 | $16,800.00 | | |
| 8/26/2021 | Patrick Lin | Insider | Buy | 4,000 | $6.02 | $24,080.00 | 422,890 | |
| 6/23/2021 | David Young | CEO | Buy | 10,000 | $7.67 | $76,700.00 | 345,190 | |
| 6/22/2021 | Robert Michael Floyd | COO | Buy | 2,000 | $7.03 | $14,060.00 | 28,000 | |
| 6/21/2021 | James H. Stanker | CFO | Buy | 1,000 | $6.81 | $6,810.00 | 36,510 | |
| 4/13/2021 | Justin W. Yorke | Director | Sell | 6,500 | $9.86 | $64,090.00 | 300,706 | |
| 4/13/2021 | Justin W. Yorke | Director | Sell | 6,500 | $9.86 | $64,090.00 | 300,706 | |
| 4/8/2021 | James E Besser | Insider | Sell | 400,000 | $10.76 | $4,304,000.00 | 1,064,300 | |
| 4/6/2021 | James E Besser | Insider | Sell | 31,771 | $10.91 | $346,621.61 | 1,064,300 | |
| 2/22/2021 | James E Besser | Major Shareholder | Sell | 20,929 | $11.56 | $241,939.24 | 1,120,000 | |
| 2/18/2021 | James E Besser | Major Shareholder | Sell | 5,000 | $11.35 | $56,750.00 | 1,120,000 | |
| 10/2/2020 | James E Besser | Major Shareholder | Buy | 30,000 | $4.04 | $121,200.00 | 405,000 | |
27 U.S. Cities Where Stocks Yield 26% a Year
From Investing Daily | Ad
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
Processa Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/23/2022 | BlackRock Inc. | 30,501 | $0.15M | 0.0% | +12.9% | 0.194% |  |
| 2/15/2022 | Coastal Bridge Advisors LLC | 32,500 | $0.16M | 0.0% | +18.2% | 0.207% | |
| 2/10/2022 | AIGH Capital Management LLC | 303,703 | $1.49M | 0.5% | -21.5% | 1.932% | |
| 1/26/2022 | Verdence Capital Advisors LLC | 63,227 | $0.31M | 0.0% | -14.3% | 0.402% | |
| 11/12/2021 | Geode Capital Management LLC | 64,902 | $0.56M | 0.0% | +73.5% | 0.416% | |
| 10/29/2021 | Janney Montgomery Scott LLC | 46,231 | $0.40M | 0.0% | -18.5% | 0.296% | |
| 8/17/2021 | Millennium Management LLC | 54,154 | $0.44M | 0.0% | -42.4% | 0.348% | |
| 8/17/2021 | Citadel Advisors LLC | 10,106 | $83K | 0.0% | -23.0% | 0.065% | |
| 8/16/2021 | State Street Corp | 16,600 | $0.14M | 0.0% | N/A | 0.107% | |
| 8/13/2021 | Geode Capital Management LLC | 37,400 | $0.31M | 0.0% | +34.4% | 0.240% | |
| 8/13/2021 | Vanguard Group Inc. | 373,171 | $3.06M | 0.0% | +136.7% | 2.397% | |
| 8/10/2021 | Coastal Bridge Advisors LLC | 27,500 | $0.23M | 0.0% | +37.5% | 0.177% | |
| 8/9/2021 | Vectors Research Management LLC | 4,000 | $33K | 0.0% | N/A | 0.026% | |
| 5/21/2021 | Citadel Advisors LLC | 13,117 | $0.14M | 0.0% | N/A | 0.085% | |
| 5/19/2021 | Worth Venture Partners LLC | 90,968 | $0.94M | 0.5% | N/A | 0.586% | |
| 5/18/2021 | Millennium Management LLC | 93,999 | $1.03M | 0.0% | -12.0% | 0.606% | |
| 5/18/2021 | Citadel Advisors LLC | 13,117 | $0.14M | 0.0% | N/A | 0.085% | |
| 5/17/2021 | Coastal Bridge Advisors LLC | 20,000 | $0.22M | 0.0% | N/A | 0.129% | |
| 5/12/2021 | Northern Trust Corp | 12,845 | $0.14M | 0.0% | N/A | 0.083% | |
| 5/12/2021 | Geode Capital Management LLC | 27,825 | $0.30M | 0.0% | N/A | 0.179% | |
| 5/12/2021 | Essex Investment Management Co. LLC | 72,908 | $0.80M | 0.1% | -2.7% | 0.470% | |
| 5/4/2021 | Commonwealth Equity Services LLC | 10,550 | $0.12M | 0.0% | N/A | 0.068% | |
| 4/27/2021 | Janney Montgomery Scott LLC | 63,331 | $0.69M | 0.0% | -4.5% | 0.408% | |
| 2/13/2021 | Essex Investment Management Co. LLC | 74,928 | $0.49M | 0.1% | N/A | 0.709% | |
Data available starting January 2016
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Read More on Processa Pharmaceuticals
Volume
392 shs
Average Volume
45,373 shs
Market Capitalization
$25.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.1
Who are the company insiders with the largest holdings of Processa Pharmaceuticals?
